期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

卵巢癌靶向治疗新进展

暂未订购
导出
摘要 由于卵巢癌至今缺乏有效的早期诊断方法,绝大多数患者在作出临床诊断时已处于晚期,虽经标准治疗（手术治疗＋辅助化疗）,临床症状缓解,生活质量提高,但多数在18～24个月后复发，且对多种化疗药物产生耐药性，
作者 蒋瑛 李惠新
机构地区 兰州大学第二医院妇产科
出处 《中国现代医药杂志》 2011年第5期133-134,共2页 Modern Medicine Journal of China
关键词 卵巢癌 靶向治疗 临床诊断 诊断方法 辅助化疗 手术治疗 标准治疗 症状缓解
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献15

  • 1Apte SM, Bucana CD, Killion JJ, et al. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecologic Oncalogy, 2004,93(1):78-86.
  • 2Ledermann JA, Rustin G J, Hackshaw A,et al. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF1120 following treatment of relapsed ovarian cancer (OC)[J].Joumal of Clinical Oncology,2009, 27(15S) :5501.
  • 3Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer [J]. Gynecologic Oncology,2008,108:619-626.
  • 4Sausville E, EoRusso P, Quinn M, et al. A phase I study of EC145 administered weeks 1 and 3 of a g-week cycle in patients with refractory solid tumors [J]. Journal of Clinical Oncology, 2007,25(18S) : 2577.
  • 5Naumann RW, Symanowski JT, Ghamande SA, et al. PRECE- DENT:A randomized phase II trial comparing EC145 and pegy- lated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer[J]. Journal of Clinical Oncology ,2010,28(18S):LBA5012.
  • 6李季林,肖建,于如同.肿瘤抑制基因PTEN研究新进展[J].现代肿瘤医学,2010,18(5):1034-1037. 被引量：18
  • 7Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sen- sitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D and c-myc expression [J]. The Journal of Biological Chemistry, 2004,279(4):2737-2746.
  • 8Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits hu- man ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model[J]. Clinical Cancer Research, 2007,13(14):4261-4270.
  • 9Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirollmus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies [J]. Gynecologic Oncology, 2010, 117(3):473-476.
  • 10崔晓娟,喇端端.卵巢癌的靶向治疗进展[J].实用医学杂志,2010,26(3):519-521. 被引量：6

二级参考文献99

  • 1Gordon A N, Fleagle J T, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase Ⅲ study of pegylated liposomal doxorubuein versus topoteean [J]. J Clin Oncol , 2001,19 (14) : 3312- 3222.
  • 2Wright J D, Secord A A, Numnum T M, et al. A muhi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer [J]. Int J Gynecol Cancer,2008,18(3) : 400-406.
  • 3Garcia A A, Hirte H, Fleming G, et al. Phase Ⅱ clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California,Chicago, and Princess Margaret Hospital phase Ⅱ consortia [J]. J Clin Oncol, 2008, 26 (1):76-82.
  • 4Tew W P, Colombo N, Ray-Coquard A, et al. VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer: preliminary results of a randomized, multicentre phase Ⅱ study [J]. Proc Am Soc Clin Oncol, 2007, 25 (18s) : 5508a.
  • 5Welch S, Hirte H, Schilder R J, et al. Phase Ⅱ study of sorafenib (BAY43- 90006) in combination with gemcitabine in recurrent epithelial ovarian cancer: PMH phase Ⅱ consortium trial [J]. Proc Am Soc Clin Oncol, 2006, 24(18s): 5084a.
  • 6Azad N S, Posadas E M, Kwitkowski V E, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity [J]. J Clin Oncol, 2008,26 (22) :3709- 3714.
  • 7Servidei T, Riccardi A, Mozzetti S, et al. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib [J]. Int J Cancer. 2008 , 123(12) :2939-2949.
  • 8Schilder R J, Sill M W, Chen X, et al. Phase Ⅱ study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: Gynecologic Oncology Group Study [J]. Clin Cancer Res, 2005,11 (15) :5539 - 5548.
  • 9Pautier P, Joly F, Kerbrat P, et al. Gefitinib in combination with paclitaxel and carboplatin as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma : Final results of a phase Ⅱ study [ J J. J Olin Oncol, 2007,25 ( 185 ) : 5566.
  • 10Schilder R J, Pathak H B, Lokshin A E, et al. Phase Ⅱ trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash [ J ]. Gynecol Oncol, 2009. 113(1) :21-27.

共引文献26

中国现代医药杂志
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部